Analysts’ Recent Ratings Changes for Artivion (AORT)

Several analysts have recently updated their ratings and price targets for Artivion (NYSE: AORT):

• 8/18/2026 – Artivion had its price target raised by Canaccord Genuity Group Inc. from $39.00 to $40.00. They now have a “buy” rating on the stock.
• 8/15/2026 – Artivion was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/11/2026 – Artivion was downgraded by Weiss Ratings from “sell (d+)” to “sell (d-)”.
• 8/7/2026 – Artivion was given a new $39.00 price target by Canaccord Genuity Group Inc..
• 7/21/2026 – Artivion had its “market outperform” rating reaffirmed by Citigroup Inc..
• 7/20/2026 – Artivion had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $44.00 price target on the stock.

Insider Activity at Artivion

In related news, SVP Jean F. Holloway sold 977 shares of Artivion stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total transaction of $27,834.73. Following the sale, the senior vice president directly owned 184,118 shares of the company’s stock, valued at $5,245,521.82. This trade represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Andrew M. Green sold 44,001 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the completion of the transaction, the senior vice president directly owned 60,259 shares of the company’s stock, valued at approximately $1,247,361.30. This trade represents a 42.20% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 114,978 shares of company stock worth $2,965,155. Company insiders own 6.30% of the company’s stock.

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.